Schizophrenia

Tovani does not treat this with ketamine

This page is here for honesty and completeness. Ketamine is not an appropriate treatment for Schizophrenia, and in some cases it is contraindicated. Below is what the condition is and the treatments that genuinely help — and where, if at all, ketamine has any narrow role (usually only for a separate co-occurring depression). If you’re in crisis, call or text 988.

The short version

●Schizophrenia is a chronic psychotic disorder involving hallucinations, delusions, disorganized thinking, and "negative symptoms" (reduced motivation, flat affect, social withdrawal).
●It is treatable: antipsychotic medication plus psychosocial support (therapy, supported employment, family education) is the foundation, and early intervention improves outcomes.
●Ketamine is NOT a treatment for schizophrenia — it transiently induces psychotic-like symptoms, and active psychosis is a contraindication to ketamine.¹
●Tovani does not treat schizophrenia, and active psychotic disorders are screened out at eligibility for safety.
●The right care is a psychiatrist experienced in psychotic disorders — not ketamine.
●The only adjacent role ketamine could ever have is treating a clearly separate, stabilized comorbid depression under specialist supervision — not the psychosis, and not in an at-home model.

Clinical definition

Schizophrenia is a chronic, often disabling psychiatric disorder characterized by psychosis. DSM-5 requires two or more of the following for a significant portion of a month, with continuous signs for at least six months: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms (diminished emotional expression or avolition), with at least one being delusions, hallucinations, or disorganized speech. The illness includes positive symptoms (hallucinations, delusions), negative symptoms (reduced motivation, flat affect, social withdrawal, poverty of speech), and cognitive impairment (attention, memory, executive function), the latter two of which drive much of the long-term disability. It typically emerges in late adolescence or early adulthood, involves dopaminergic and other neurotransmitter dysregulation, and has a strong genetic component. Crucially for ketamine: NMDA-receptor antagonism (ketamine's mechanism) is itself a model of psychosis — ketamine transiently reproduces positive, negative, and cognitive features of schizophrenia in healthy people — which is exactly why it is contraindicated in active psychotic disorders.

How it differs from related conditions

vs. Schizoaffective disorder

Schizoaffective disorder includes prominent mood episodes alongside psychosis; schizophrenia's mood symptoms, if present, are less prominent and not the core.

vs. Bipolar disorder with psychotic features

Psychosis occurs only during mood episodes in bipolar disorder; in schizophrenia, psychosis persists outside of mood episodes.

vs. Substance-induced psychosis

Psychosis directly caused by a substance (including ketamine) resolves with abstinence; schizophrenia persists independently.

vs. Major depression with psychotic features

Here psychosis is mood-congruent and tied to a depressive episode, distinct from the primary psychosis of schizophrenia.

First-line treatments

Antipsychotic medication

The foundation of treatment — second-generation antipsychotics reduce positive symptoms and relapse; clozapine is uniquely effective for treatment-resistant schizophrenia.

Psychosocial interventions

CBT for psychosis, supported employment/education, social-skills training, and family psychoeducation improve functioning and reduce relapse.

Coordinated specialty care / early intervention

Team-based early intervention after a first episode meaningfully improves long-term outcomes.

Long-acting injectable antipsychotics

Improve adherence and reduce relapse for many patients.

When standard treatments fail

When schizophrenia does not respond to two adequate antipsychotic trials, it is treatment-resistant, and clozapine — the most effective antipsychotic for this group — is indicated and underused. Other steps include ECT augmentation in selected cases, optimizing psychosocial support, and treating co-occurring substance use and depression. Ketamine is not part of this pathway and is contraindicated in active psychosis; it is not a treatment-resistance option for schizophrenia.

Where ketamine fits

Ketamine is contraindicated in schizophrenia and active psychotic disorders — this is one of the clearest places where the honest answer is no. Ketamine works by blocking NMDA receptors, and NMDA antagonism is itself a well-established pharmacological model of psychosis: in healthy volunteers ketamine transiently reproduces hallucination-like, delusion-like, negative, and cognitive symptoms of schizophrenia (Rosburg 2018), and in people with a psychotic disorder it can worsen or precipitate psychosis. For this reason active psychosis is a standard contraindication to therapeutic ketamine (Sanacora 2017). The only narrow, theoretical scenario is a separate, fully stabilized comorbid depression managed by a psychiatrist who specializes in psychotic disorders — and even that is not an at-home setting. Schizophrenia is treatable with the right care; ketamine is not that care.

Where this fits with Tovani

Tovani does not treat schizophrenia or active psychotic disorders, and eligibility screening specifically excludes active psychosis for safety, because ketamine can worsen it. Anyone with schizophrenia is best served by a psychiatrist experienced in psychotic disorders, coordinated specialty care, and antipsychotic treatment — the genuinely effective options. This page exists so that the answer to "ketamine for schizophrenia" is clear and honest: it is not appropriate, and we will say so.

Check eligibility Find treatment options The science behind ketamine

Frequently asked

Can ketamine treat schizophrenia?

No — and it can make it worse. Ketamine blocks NMDA receptors, and that mechanism is actually used to model psychosis: it transiently produces schizophrenia-like symptoms in healthy people and can worsen psychosis in those who have it. Active psychosis is a contraindication to ketamine. Schizophrenia is treated with antipsychotics and psychosocial support.

Why is ketamine contraindicated in psychosis?

Because NMDA-receptor antagonism — how ketamine works — reproduces and can trigger psychotic symptoms. Giving it to someone with a psychotic disorder risks worsening or precipitating psychosis, which is why it's excluded at screening.

What actually treats schizophrenia?

Antipsychotic medication is the foundation (with clozapine uniquely effective for treatment-resistant cases), combined with psychosocial interventions — CBT for psychosis, supported employment, family education — and, ideally, early coordinated specialty care. Outcomes are meaningfully better with the right team.

I have schizophrenia and depression — is ketamine an option?

Not in an at-home model, and not for the psychosis. The only narrow scenario is a fully stabilized, clearly separate depression managed by a psychiatrist who specializes in psychotic disorders, weighing the real risks. Tovani is not the right setting for this; specialist psychiatric care is.

References

McCutcheon RA et al. 2020, JAMA Psychiatry — Overview of schizophrenia — symptoms, neurobiology, and the antipsychotic and psychosocial treatments that are first-line. (PMID 31664453)
Rosburg T & Schmidt A 2018, Frontiers in Behavioral Neuroscience — Mechanisms of ketamine-induced psychotic-like symptoms — the basis for NMDA antagonism as a model of psychosis and for ketamine's contraindication in psychosis. (PMID 30618662)
Sanacora G et al. 2017, JAMA Psychiatry — APA consensus on ketamine, which lists active psychotic disorders among contraindications. (PMID 28249076)

Last reviewed by Dr. Ben Soffer, DO on May 31, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.